News

Special Sections

Edward Kim | Equities.com |

Artificial intelligence points to a rheumatoid arthritis drug that may be a viable treatment for the new virus.


Michael McTague | Equities.com |

In this new series, we examine singular industry economies, beginning with Russia.


Reuters | Equities.com |

The drugmaker expects the two new treatments to bring in combined revenue of $1.7 billion in 2020.


Edward Kim | Equities.com |

Risdiplam showed medically-meaningful and statistically significant results patients with type 2 and type 3 SMA.


Reuters | Equities.com |

Total kept fourth quarter profit steady at $3.2 billion despite low oil prices and fulfilled a pledge to boost dividends.


Edward Kim | Equities.com |

Company's earnings missed estimates. Separation plan will take two years.


AP News | Equities.com |

Women's health and some of its older drugs and biosimilars to be spun off into a new company via tax-free distribution to shareholders.


Edward Kim | Equities.com |

2.5% of the pediatric population suffers from peanut allergies.


Reuters | Equities.com |

Shares were up 4.5% in London as company beats forecasts for 12th quarter in a row.


Reuters | Equities.com |

Brent crude was down 48 cents at $56.14 a barrel by 1320 GMT, having earlier lost more than $1 to its lowest since January last year at $55.42.



Discover: Trending Events

United Nations
EU Parliament
Humanity 2.0
World Economic Forum